
Sign up to save your podcasts
Or


Christian Klein is a longtime and key member of the protein and antibody community. In this episode, he speaks with Executive Conference Producer, Christina Lingham, on how the field has changed since their first collaboration. Dr. Klein offers an overview of the latest applications of bispecific antibodies, including the latest progress of clinical trials by Roche and others. He also explains how the PD1-X molecule is unique and can increase specificity of therapeutics even more.
By Cambridge Healthtech Institute4.8
2525 ratings
Christian Klein is a longtime and key member of the protein and antibody community. In this episode, he speaks with Executive Conference Producer, Christina Lingham, on how the field has changed since their first collaboration. Dr. Klein offers an overview of the latest applications of bispecific antibodies, including the latest progress of clinical trials by Roche and others. He also explains how the PD1-X molecule is unique and can increase specificity of therapeutics even more.

3,982 Listeners

762 Listeners

111,929 Listeners

123 Listeners

10,220 Listeners

321 Listeners

6,066 Listeners

10,024 Listeners

34 Listeners

20 Listeners

2,066 Listeners